Revenue: As of FY2026 Q1, the actual value is USD 9.131 M.EPS: As of FY2026 Q1, the actual value is USD -0.22.EBIT: As of FY2026 Q1, the actual value is USD -3.121 M.<h4>Net Revenue</h4>坎伯兰药业 (Cumberland Pharmaceuticals Inc.) reported net revenues of $9.1 million for the first quarter of 2026, marking a 5% increase compared to the first quarter of 2025, after excluding a $3 million milestone payment from the prior year related to Vibativ® approval in China. The total net revenues for Q1 2026 were $9,131,317, a decrease from $11,713,055 in Q1 2025.Revenue breakdown for 坎伯兰药业’s branded portfolio in Q1 2026 included $1.0 million from Kristalose®, $2.9 million from Sancuso®, $2.1 million from Vibativ®, $1.0 million from Caldolor®, and $1.9 million from Talicia®.<h4>Operating Expenses</h4>Total operating expenses for Q1 2026 were $12.3 million. Cost of products sold was $1,933,889 in Q1 2026, up from $1,425,714 in Q1 2025. Selling and marketing expenses increased to $5,064,875 in Q1 2026 from $4,231,980 in Q1 2025. Research and development expenses were $1,458,436 in Q1 2026, an increase from $1,295,076 in Q1 2025. General and administrative expenses rose to $2,554,475 in Q1 2026 from $2,463,008 in Q1 2025. Amortization was $1,248,934 in Q1 2026, up from $1,005,330 in Q1 2025.<h4>Profitability</h4>坎伯兰药业 reported a net loss of approximately -$3.3 million for the first quarter of 2026, contrasting with a net income of $1,248,184 in Q1 2025. The company experienced an operating loss of -$3,129,292 in Q1 2026, compared to an operating income of $1,291,947 in Q1 2025. Net loss attributable to common shareholders was -$3,289,639 in Q1 2026, compared to a net income of $1,257,068 in Q1 2025. Adjusted loss for the quarter was -$1.9 million, or -$0.13 per share for Q1 2026, while adjusted earnings were $2,397,743 or $0.16 per share for Q1 2025.<h4>Balance Sheet Highlights (as of March 31, 2026)</h4><ul><li>Total assets stood at $71.0 million ($70,995,020).</li><li>Cash and cash equivalents were $11.0 million ($11,007,245), a decrease from $11,444,693 at December 31, 2025.</li><li>Total liabilities amounted to $49.7 million ($49,692,008), including $5.2 million ($5,240,733) on the company’s credit facility.</li><li>Total shareholders’ equity was $21.6 million ($21,636,524).</li></ul><h4>Cash Flow from Operating Activities</h4>Net cash provided by operating activities was $387,025 for the three months ended March 31, 2026, a decrease from $3,898,517 for the same period in 2025. Net cash used in investing activities was -$61,173 in Q1 2026, compared to -$1,228,186 in Q1 2025. Net cash used in financing activities was -$763,300 in Q1 2026, compared to -$5,526,102 in Q1 2025. The net decrease in cash and cash equivalents was -$437,448 in Q1 2026, compared to -$2,855,771 in Q1 2025. Cash and cash equivalents at the end of the period were $11,007,245 in Q1 2026, compared to $15,108,413 in Q1 2025.<h4>Outlook / Guidance</h4>坎伯兰药业 (Cumberland Pharmaceuticals Inc.) announced a strategic transaction with Apotex Inc. for the acquisition of its portfolio of FDA-approved brands for $100 million in cash, pending shareholder approval. This transaction aims to enable 坎伯兰药业 to sharpen its focus on advancing its pipeline of differentiated product candidates, particularly ifetroban, for unmet medical needs. The company will retain its development programs and majority ownership in Cumberland Emerging Technologies, positioning itself as an innovative, development-stage biopharmaceutical organization.

Cumberland Pharma | 8-K: FY2026 Q1 Revenue: USD 9.131 M